Anti-CD30 (Brentuximab Vedotin), Chimeric Antibody

Anti-CD30 (Brentuximab Vedotin), Chimeric Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is an antibody-drug conjugate that targets CD30. The conjugate consists of an Anti-CD30 human-mouse chimeric IgG1 antibody that is linked to a microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon internalization in the cell, the MMAE is detached from the antibody due to proteolytic cleavage. The MMAE then disrupts the microtubule network, which causes cell cycle arrest and results in apoptosis of tumorigenic cells. The original drug received approval from the FDA to treat adult patients with relapsed or refractory Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma.

Immunogen Sequence:Human CD30

Target Alternative Name:cAC10-vcMMAE, SGN 35, SGN-35, Ki-1, D1S166E, TNFRSF8

Species Reactivities:Human

Tag Line:The biosimilar is an antibody-drug conjugate that targets CD-30, which is highly expressed on tumor cells. Upon detachment from the antibody inside the cell, the drug disrupts the microtubule network, which leads to cell cycle arrest, and apoptosis of malignant cells

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.